EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial

Annabel J Curle, Shaline V Fazal, Shamma Qarin, Sarah K Howlett, Xiaoling He, Athena Stamper, Venkat Pisupati, Roger A Barker, Joanne L Jones

Stem Cell Reports · 2026

DOI: 10.1016/j.stemcr.2026.102818 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Stem Cell Reports, 2026. Verfasst von Annabel J Curle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Neurosciences Department, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Dopaminergic Neurons, Human Embryonic Stem Cells, Neural Stem Cells, Parkinson Disease. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Europe Excellent Science, Rosetrees, National Spectrum Consortium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease involves the progressive loss of dopaminergic neurons, prompting clinical trials replacing cell loss with neural grafts. This includes the transplantation of pluripotent stem cell-derived mesencephalic dopaminergic neural progenitors (mesDAp), including the RC17 human embryonic stem cell (hESC)-derived cells currently under investigation in the European STEM-PD trial (NCT05635409). To assess potential immune rejection risk, we characterized RC17-mesDAp immunogenicity in vitro, comparing them to human fetal ventral mesencephalic tissue (hfVM), as successfully used in similar clinical trials such as TRANSEURO. Although RC17-mesDAp expressed MHC class I, upregulated by pro-inflammatory cytokines, no peripheral immune response was detected in vitro. Instead, cells exhibited immunomodulatory effects, reducing T cell CD25 expression and proliferation. Transcriptomic analysis showed that both RC17-mesDAp and hfVM upregulated antigen-processing pathways in response to IFN-γ yet remained non-immunogenic. Findings support the immunological safety of RC17-mesDAp and suggest a set of in vitro assays that may be applicable for the preclinical evaluation of other human stem cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dopaminergic NeuronsHuman Embryonic Stem CellsNeural Stem CellsParkinson DiseaseHumansCell DifferentiationCell ProliferationGene Expression ProfilingMesencephalon

Stichwörter der Autor:innen

Parkinson’s diseasecell therapyclinical trialimmunogenicityregenerative medicinestem cells

Autor:innen und Institutionen

  • Clinical Neurosciences Department, University of Cambridge, Cambridge, UK.
  • Clinical Neurosciences Department, University of Cambridge, Cambridge, UK; Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, UK.
  • Clinical Neurosciences Department, University of Cambridge, Cambridge, UK. Electronic address: jls53@medschl.cam.ac.uk.

Förderung

  • Horizon Europe Excellent Science
  • Rosetrees
  • National Spectrum Consortium
  • UK Regenerative Medicine Platform
  • Cambridge Trust
  • Horizon 2020
  • John Black Charitable Foundation
  • Wellcome Trust

Zitieren

APA

Curle, A. J., Fazal, S. V., Qarin, S., Howlett, S. K., He, X., Stamper, A., Pisupati, V., Barker, R. A., & Jones, J. L. (2026). The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2026.102818

Vancouver

Curle AJ, Fazal SV, Qarin S, Howlett SK, He X, Stamper A, et al. The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial. Stem Cell Reports. 2026. doi:10.1016/j.stemcr.2026.102818

BibTeX
@article{Curle2026,
  author = {Curle, Annabel J and Fazal, Shaline V and Qarin, Shamma and Howlett, Sarah K and He, Xiaoling and Stamper, Athena and Pisupati, Venkat and Barker, Roger A and Jones, Joanne L},
  title = {The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial},
  journal = {Stem Cell Reports},
  year = {2026},
  doi = {10.1016/j.stemcr.2026.102818}
}
Kostenlos starten →